Meitav Investment House’s Revolution Medicines RVMD Stock Holding History

Meitav Investment House’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.15M	Buy	+11,500	New	+$1.68M	0.01%	188

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

NNPTE

Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return

MGB

Mass General Brigham Somerville, Massachusetts $361M AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Meitav Investment House's RVMD Position: Q2 2026 in Review

Meitav Investment House opened a new position in Revolution Medicines (RVMD) in Q2 2026: 11,500 shares worth $2.15M. The stake represents 0.01% of the portfolio and ranks #188 among its holdings.

294 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Meitav Investment House held 11,500 shares of Revolution Medicines worth $2.15M as of Q2 2026.
Revolution Medicines was a new Meitav Investment House position in Q2 2026.
Revolution Medicines made up 0.01% of Meitav Investment House's portfolio in Q2 2026, its #188 holding.
294 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Meitav Investment House's 13F filing for Q2 2026, filed 20 Jul 2026.